Problems of therapy and search for curative options in infantile acute B-cell lymphoblastic leukemia: a clinical case

Infantile acute B-cell lymphoblastic leukemia (B-ALL) is a rare leukemia that develops in children of the first year of life, prone to an aggressive course, a combination of unfavorable prognostic factors, frequent relapses and “switching” of tumor cell differentiation from lymphoid to myeloid. In addition, the physiological features and high vulnerability of the infant's body to the influence of unfavorable external factors cause a high frequency of severe complications of both the underlying disease and the specific treatment, which limits the possibilities of therapy and reduces the likelihood of a favorable outcome in such patients. In this regard, there is no doubt that the search for new curative options that increase the effectiveness and reduce the toxicity of therapy for B-ALL in infants is highly relevant. Given the rarity of this type of leukemia, fundamental studies of the biology of infantile leukemia, extensive clinical trials, and exchange of experience between transplant centers involved in the treatment of such patients are important for improving the effectiveness of its therapy. The clinical case presented in this article demonstrates the main problems of therapy for infantile B-ALL: the initial presence of a set of unfavorable prognostic factors (MLL gene rearrangement, lack of CD10 expression on tumor cells, age under 3 months, hyperleukocytosis, and central nervous system damage at manifestation), “switching” of the blast cell line from lymphoid to myeloid, poor response to glucocorticosteroids and development of severe complications limiting the possibilities of therapy intensification already at the stage of induction therapy, refractory course, relapse at late stages after allogeneic hematopoietic stem cell transplantation. Moreover, an individualized approach and the use of new treatment methods, including immunotherapy, cell therapy and apoptosis inducers, allowed the patient to achieve clinical and hematological remission with negative minimal residual disease a year after allogeneic hematopoietic stem cell transplantation, even after a relapse of leukemia.

1. Knez V., Liu X., Schowinsky J., Pan Z., Wang D., Lorsbach R., Lu C., Luedke C., Haag M., Carstens B., Swisshelm K., Yang L.H., Jug R., Wang E., Liang X. Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study. Leuk Lymphoma. 2019;60(4):1006–13. doi: 10.1080/10428194.2018.1508667.

2. Van der Linden M., Valsecchi M., De Lorenzo P., Möricke A., Janka G., Leblanc T.M., Felice M., Biondi A., Campbell M., Hann I., Rubnitz J.E., Stary J., Szczepanski T., Vora A., Ferster A., Hovi L., Silverman L.B., Pieters R. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009;114:3764–8. doi: 10.1182/blood-2009-02-204214.

3. Kang H., Wilson C., Harvey R. Gene expression profi les predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2012;119:1872–81. doi: 10.1182/blood-2011-10-382861.

4. Mansoor N., Imran S., Maqsood S., Pasha S., Jabbar N. Infantile B-lymphoblastic leukemia: a case series and review of the literature. J Int Med Res. 2023;51(4):3000605231167789. doi: 10.1177/03000605231167789.

5. Neupane P., Dahal P., Acharya B. A case report on acute lymphoblastic leukemia in a 10 days old neonate. Am J Med Case Rep. 2015;3:95–7. doi: 10.12691/ajmcr-3-4-2.

6. Pieters R., Schrappe M., De Lorenzo P., Hann I., De Rossi G., Felice M., Hovi L., LeBlanc T., Szczepanski T., Ferster A., Janka G., Rubnitz J., Silverman L., Stary J., Campbell M., Li C.-K., Mann G., Suppiah R., Biondi A., Vora A., Grazia Valsecchi M. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomized trial. Lancet. 2007;370:240–50. doi: 10.1016/S0140-6736(07)61126-X.

7. Jiang J.-G., Roman E., Nandula S.V., Murty V.V.S., Bhagat G., Alobeid B. Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) ranslocations and JH gene rearrangement. Leuk Lymphoma. 2005;46:1223–7. doi: 10.1080/10428190500086055.

8. Brown P., Pieters R., Biondi A. How I treat infant leukemia. Blood. 2019;133(3):205–14. doi: 10.1182/blood-2018-04-785980.

9. Mann G., Attarbaschi A., Schrappe M., De Lorenzo P., Peters C., Hann I., De Rossi G., Felice M., Lausen B., Leblanc T., Szczepanski T., Ferster A., Janka-Schaub G., Rubnitz J., Silverman L.B., Stary J., Campbell M., Li C.K., Suppiah R., Biondi A., Vora A., Valsecchi M.G., Pieters R.; Interfant-99 Study Group. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010;116(15):2644–50. doi: 10.1182/blood-2010-03-273532.

10. Driessen E.M.C., de Lorenzo P., Campbell M., Felice M., Ferster A., Hann I., Vora A., Hovi L., Escherich G., Li C.K., Mann G., Leblanc T., Locatelli F., Biondi A., Rubnitz J., Schrappe M., Silverman L., Stary J., Suppiah R., Szczepanski T., Valsecchi M., Pieters R. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30(5):1184–7. doi: 10.1038/leu.2015.246.

11. Gardner R., Wu D., Cherian Min Fang S., Hanafi L.-A., Finney O., Smithers H., Jensen M.C., Riddell S.R., Maloney D.G., Turtle C.J. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–10. doi: 10.1182/blood-2015-08-665547.

12. Matsui M., Yasu T., Makimoto A., Yuza Y. Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML). Cancer Chemother Pharmacol. 2024;95(1):1. doi: 10.1007/s00280-024-04730-z.

13. Rayes A., McMasters R.L., O'Brien M.M. Lineage switch in MLLrearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63(6):1113–5. doi: 10.1002/pbc.25953.

14. Mejstríková E., Hrusak O., Borowitz M.J., Whitlock J.A., Brethon B., Trippett T.M., Zugmaier G., Gore L., von Stackelberg A., Locatelli F. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659. doi: 10.1038/s41408-017-0023-x.